Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2017

Plasma lipoprotein subfraction concentrations are associated
with lipid metabolism and age-related macular degeneration
Chui Ming Gemmy Cheung
National University of Singapore

Alfred Gan
Singapore Eye Research Institute

Qiao Fan
National University of Singapore

Miao Ling Chee
Singapore Eye Research Institute

Rajendra S. Apte
Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Gemmy Cheung, Chui Ming; Gan, Alfred; Fan, Qiao; Chee, Miao Ling; Apte, Rajendra S.; Khor, Chiea Chuen;
Yeo, Ian; Mathur, Ranjana; Cheng, Ching-Yu; Wong, Tien Yin; and Tai, E. Shyong, ,"Plasma lipoprotein
subfraction concentrations are associated with lipid metabolism and age-related macular degeneration."
Journal of Lipid Research. 58,9. 1785-1796. (2017).
https://digitalcommons.wustl.edu/open_access_pubs/6280

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Chui Ming Gemmy Cheung, Alfred Gan, Qiao Fan, Miao Ling Chee, Rajendra S. Apte, Chiea Chuen Khor, Ian
Yeo, Ranjana Mathur, Ching-Yu Cheng, Tien Yin Wong, and E. Shyong Tai

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/6280

Supplemental Material can be found at:
http://www.jlr.org/content/suppl/2017/07/11/jlr.M073684.DC1
.html

 Author’s Choice

Plasma lipoprotein subfraction concentrations are
associated with lipid metabolism and age-related
macular degeneration
Chui Ming Gemmy Cheung,1,*,†,*** Alfred Gan,* Qiao Fan,§ Miao Ling Chee,* Rajendra S. Apte,**
Chiea Chuen Khor,†† Ian Yeo,*,*** Ranjana Mathur,*,*** Ching-Yu Cheng,*,*** Tien Yin Wong,*,†,***
and E. Shyong Tai§§

ORCID IDs: 0000-0003-3358-3516 (C.M.G.C.); 0000-0003-3072-2293 (Q.F.); 0000-0003-2281-2336 (R.S.A.);
0000-0002-4385-2145 (I.Y.); 0000-0002-9262-7120 (R.M.); 0000-0002-8279-3213 (C-Y.C.); 0000-0002-8448-1264
(T.Y.W.); 0000-0003-2929-8966 (E.S.T.)

Abstract Disturbance in lipid metabolism has been suggested as a major pathogenic factor for age-related macular
degeneration (AMD). Conventional lipid measures have
been inconsistently associated with AMD. Other factors that
can alter lipid metabolism include lipoprotein phenotype
and genetic mutations. We performed a case-control study to
examine the association between lipoprotein profile and
neovascular AMD (nAMD) and whether the cholesterylester
transfer protein (CETP) D442G mutation modulates these
associations. Patients with nAMD had significantly higher
concentrations of HDL and IDL compared with controls.
The increase in HDL particles in nAMD patients was driven
by an excess of medium-sized particles. Concurrently, patients with nAMD also had lower Apo A-1, lower VLDL and
chylomicron lipoprotein. Many of these associations showed
a dose-dependent association between controls, early AMD
cases, and nAMD cases. Adjustment for the presence of the
D442G mutation at the CETP locus did not significantly alter the increased AMD risk associated with HDL particle
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concentration. AMD is associated with variation in many
lipoprotein subclasses, including increased HDL and IDL
particles and decreased Apo A-1, VLDL, and chylomicron
particles. These data suggest widespread systemic disturbance in lipid metabolism in the pathogenesis of AMD,
including possible alterations in lipoprotein carrier capacity.—Cheung, C. M. G., A. Gan, Q. Fan, M. L. Chee, R. S. Apte,
C. C. Khor, I. Yeo, R. Mathur, C–Y. Cheng, T. Y. Wong, and
E. S. Tai. Plasma lipoprotein subfraction concentrations are
associated with lipid metabolism and age-related macular
degeneration. J. Lipid Res. 2017. 58: 1785–1796.
Supplementary key words high density lipoprotein • genetics • cholesterylester transfer protein

Age-related macular degeneration (AMD) is one of the
major causes of blindness worldwide (1, 2). Despite extensive research, the pathogenesis of AMD remains elusive
and is likely multifactorial, involving genetic, lifestyle, and
systemic factors (3–5). Current treatment in the form of
anti-vascular endothelial growth factor therapy mainly
addresses the specific angiogenic complications of neovascular AMD (nAMD). However, the response to these
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OR, odds ratio; RPE, retinal pigment epithelium; TG, triglyceride;
VLDLR, VLDL receptor.
1
To whom correspondence should be addressed.
e-mail: gemmy.cheung.c.m@snec.com.sg
The online version of this article (available at http://www.jlr.org)
contains a supplement.

Copyright © 2017 by the American Society for Biochemistry and Molecular Biology, Inc.
This article is available online at http://www.jlr.org

Journal of Lipid Research Volume 58, 2017

1785

Downloaded from www.jlr.org at Washington Univ Medical Library, on October 26, 2017

Singapore Eye Research Institute,* Singapore National Eye Centre, Singapore; Department of Ophthalmology,
Yong Loo Lin School of Medicine,† and Department of Medicine, Cardiovascular and Metabolic Disorders
Programme,§§ National University of Singapore, Singapore; Centre for Quantitative Medicine,§ and
Ophthalmology and Visual Sciences Program,*** Duke-NUS Medical School, National University of
Singapore, Singapore; Ophthalmology and Visual Sciences,** Developmental Biology and Medicine,
Washington University School of Medicine, St. Louis, MO; and Genome Institute of Singapore,†† Singapore

Supplemental Material can be found at:
http://www.jlr.org/content/suppl/2017/07/11/jlr.M073684.DC1
.html

1786

Journal of Lipid Research Volume 58, 2017

and AMD. We also explored the possibility that the CETP
D442G mutation may mediate or modulate these associations. Our hypothesis is that patients with AMD have abnormal lipid metabolism, which may give rise to abnormal
lipoprotein profile characterized by an increase in large
HDL particles, which are inefficient carriers of cholesterol.

METHODS
Study design and participants
We performed a case-control study utilizing serum from 193
participants of Chinese ethnicity with nAMD enrolled in a prospective clinical cohort study, the Asian AMD Phenotyping Study;
and 184 subjects with early AMD and 289 age and gender-matched
controls free of AMD enrolled in the Singapore Chinese Eye Study.
Both studies were approved by the Singhealth Institutional Review
Board and were conducted in accordance with the Declaration of
Helsinki (protocol nos. R697/47/2009 and R498/47/2006). Detailed methodology of both studies has been published previously
(36–42), and all participants provided written informed consent
(additional information is available in supplemental data).
The Asian AMD Phenotyping Study prospectively recruited
a consecutive series of treatment-naıve Asian patients with exudative maculopathy secondary to nAMD from the retinal clinic of
the Singapore National Eye Centre since March 1, 2010, and is
still ongoing (32–37). To facilitate comparison of potential risk
factors, the Asian AMD Phenotyping study adopted methods
modeled after the Singapore Epidemiology of Eye Disease program, which enrolled more than 10,000 participants by using
standardized methodology and photographic grading of AMD
and risk factor assessment. The Singapore Chinese Eye Study is
part of the Singapore Epidemiology of Eye Disease program
and is a population-based cohort study of major eye diseases in
urban Chinese adults ranging from 40 to 80 years of age residing
in Singapore (42). Subjects were selected from a computergenerated list provided by the Singapore Ministry of Home Affairs, using an age-stratified (by 10 year age groups) random sampling method. The study took place between 2009 and 2011. A
total of 3,353 Chinese persons were eligible, and 72.8% participated in the study. Subjects with early AMD and age- and gendermatched controls without AMD were selected from this cohort.

Clinical evaluation
nAMD cases. Each patient was examined at baseline according
to a standardized protocol derived in part from the Singapore
Chinese Eye Study (42, 43). The examination procedures included measurements of height, weight, blood pressure, and
pulse rate, followed by a comprehensive ocular examination (visual acuity, dilated fundus examination, color fundus photography, fluorescein angiography, indocyanine green angiography,
and spectral domain optical coherence tomography). nAMD was
diagnosed clinically and confirmed by ocular imaging results,
which were graded by retinal specialists.
Early AMD cases and non-AMD controls. All participants had an
interview, systemic examination and laboratory investigations to
determine socioeconomic, ocular, and systemic risk factors. We
used a digital fundus camera to capture color photographs of
each eye after pupil dilation. Photograph of at least one eye of
sufficient quality for assessment of AMD status was available in
3,312 participants (98.8%). The Centre for Vision Research, University of Sydney, performed AMD grading using a modification of
the Wisconsin Age-Related Maculopathy Grading System (43), which
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drugs varies among individuals, and some eyes are unresponsive to this therapy (6–10). Additional pathways other
than angiogenesis may also play significant roles in the pathogenesis of AMD and provide potential alternative means of
therapy.
In this regard, several pathways have been implicated in
the pathogenesis of AMD, including chronic inflammation,
atherosclerosis, and lipid dysregulation (3, 4, 11–16). A possible link between lipids and AMD has been suggested, and,
recently, high-dose statins were reported to lead to resolution of signs of AMD and vision improvement (17, 18).
However, the relationship between lipids and AMD has
been inconsistently documented, with most studies only examining conventional measures of plasma lipids [i.e., total
cholesterol, triglycerides (TGs), HDL-C and LDL-C] and
AMD. Plasma lipids are carried on a heterogenous group of
lipoproteins, variations in the size and density of which can
alter lipid function. Importantly, within the retina, there is
evidence that a sophisticated system of cholesterol uptake,
intracellular trafficking, storage, and elimination utilizing lipoproteins as intermediates plays an important role
in retinal physiology (19–21). Lipoproteins derived from
plasma have also been implicated as the major upstream
source of fatty acids within Bruchs’ membrane and provide
an energy source to the retina (19, 22, 23), in addition to
performing important functional roles in the transport of
C, vitamin E, lutein, and zeaxanthin for use by photoreceptors (24, 25). Detailed analyses of lipoprotein profiles have
provided important insights into the pathogenesis of other
chronic diseases, including cardiovascular disease, insulin
resistance, and diabetic retinopathy, in which endothelial
dysfunction and atherosclerosis have been implicated
(26–28). Thus, dysregulation in lipid metabolism, possibly
affecting lipoproteins, but not necessarily captured by
conventional plasma lipid measures, may also play a significant role in the pathogenesis of AMD.
In further support of this hypothesis are recent studies
that show variants in genes involved in lipid metabolism,
including hepatic lipase (LIPC), cholesterylester transfer protein (CETP), and ATP-binding cassette transporter A1
(ABCA1), confer increased risk of AMD (29–32). Animal
studies have confirmed that the reverse cholesterol pathway
regulated by ABC transporters may be critical in the development of a choroidal neovascularization (15). The proteins
encoded by most of these cholesterol-related genes have also
been immunolocalized to the retina (21). We recently completed a genome-wide association study in East Asian AMD
and have identified a missense mutation (D442G) in the
CETP gene that is associated with elevated HDL-C and an
increased risk of nAMD. CETP mediates the transfer of
cholesteryl ester from HDL to LDL (33). CETP deficiency
generates enlarged HDL particles containing an excess of
cholesteryl esters, which are thought to be dysfunctional
and incapable of reverse cholesterol transport (34, 35).
How genetic variants at the CETP locus influence or
modulate the relationship between plasma lipids, lipoproteins, and AMD is unknown.
To address these major gaps, we examined the association between lipoprotein phenotype (size and distribution)
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defines early AMD as either soft indistinct or reticular drusen or
both soft, distinct drusen plus retinal pigment epithelium (RPE)
abnormalities. Early AMD cases and age- and gender-matched subjects free of any stage of AMD were selected as controls for this study
(Fig. 1).
Medical and drug history. A detailed interviewer-administered
questionnaire was used to collect information about medical
history (including hypertension, diabetes, angina, myocardial infarction, and stroke), medication including lipid-altering drugs,
and cigarette smoking (defined as current, past, and never) in
participants of both studies. The questionnaire was administered
in English or translated into Chinese (Mandarin) and back-translated into English.

Lipids and lipoproteins

CETP genotyping and measurement
CETP D442G (rs2303790) genotype was determined from the
existing Illumina Human OmniExpress genotyping or by using

Fig. 1. Mean serum concentration of HDL particles in participants with no AMD, early AMD, and nAMD. Participants with
nAMD had significantly higher concentration of HDL compared
with participants with early AMD (37.2 vs. 34.7 µmol/l), and compared with controls (37.2 vs. 35.3 µmol/l). The increase in HDL
particles was mainly driven by an excess of medium-sized particles in participants with nAMD, which was significantly higher
compared with participants with early AMD (10.4 vs. 9.1 µmol/l)
and compared with controls (10.4 vs. 9.1 µmol/l). * P < 0.001;
** P = 0.003; #P = 0.026; ##P = 0.009.

Statistical analyses
All baseline and lipoprotein profile characteristics (LPCs) of
study participants were summarized and compared between the
three groups of study participants, namely, nAMD cases, early
AMD cases, and age- and gender-matched controls. ANOVA using
an F-test was conducted to compare the means of continuous
variables, whereas a chi-squared or Fisher’s exact test was used
to compare the proportional distribution of categorical variables between the three groups. Pairwise comparisons of the
mean of each LPC were also performed by using Tukey’s honest
significant difference test for multiple comparisons. For assessing
crudely the presence of a linear trend relating the mean of each
LPC with increasing AMD severity (from no AMD to early AMD to
nAMD), an F-test of the linear orthogonal polynomial contrast
was conducted, treating AMD severity as an equally spaced ordinal
variable in a regression model.
D442G mutation carrier status was dichotomized, with individuals carrying at least one mutant allele classified as mutation carriers. The mean of each LPC between D442G mutation carriers
and noncarriers was compared in nAMD cases and controls separately with a linear regression of the LPC against mutation status,
adjusting for potential confounders of the relationship—age, gender, BMI, current smoking status, lipid-lowering medication, hypertension, diabetes, myocardial infarction, and stroke history.
Because the mutation was very rare in the general population
(3%), the original sample of age- and gender-matched controls
had to be enriched with additional carriers of the mutation, with
the augmented sample used only in this part of the analysis.
Each LPC was hereafter standardized to its distribution within
age- and gender-matched controls for ease of comparing their effect sizes. To examine whether there was an independent association between each standardized LPC and the risk of nAMD or
early AMD, as compared against the comparably aged normal cohort, a logistic regression model that adjusted for the abovementioned potential confounders was used for each outcome. A
cumulative proportional odds model was also fitted to assess
whether change in each LPC was more generally associated with
the risk of presenting with a more severe stage of AMD, here regarding AMD status as a three-level ordinal outcome—the results
were by and large consistent with the effect estimates obtained
from the separate logistic regression models and not presented
for brevity. Whether the effect of each LPC on nAMD risk was
influenced by the D442G mutation was lastly investigated by
adding D442G mutation status as a covariate to the logistic regression models. Expanded models allowing for interaction between each LPC and D442G mutation status were also studied
to assess whether the said effects differed between mutation carriers and noncarriers. Where evidence of interaction was found,
estimates of the effect of the LPC on nAMD risk were presented
separately in carriers and noncarriers of the mutation.
All estimated effects derived from logistic regression models
were presented as odds ratios (ORs) per SD increase in each LPC.
Two-sided Wald tests and t-tests were used to test the coefficients
of interest in logistic and linear regression models, respectively,
with statistical significance concluded at P < 0.05. Ninety-five percentage confidence intervals were presented for all reported
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In both cohorts, a nonfasting venous blood sample was collected
at baseline. Lipid biochemistry was performed by standard automated methods at the Biochemistry Department at the Singapore
General Hospital, which utilized a Beckman Coulter ExC800
automated chemistry analyzer. Total cholesterol, HDL-cholesterol, TGs, and LDL-cholesterol were analyzed based on homogenous enzymatic colorimetry assay using 500 l of serum.
Serum and plasma were extracted and stored at 80°C prior to
DNA extraction.
Lipoprotein subclass levels and mean particle sizes were determined for all participants by NMR spectroscopy at LipoScience
Inc. (Raleigh, NC) as previously described (26, 28), by using
stored serum. Each NMR measurement produces the concentrations of three subclasses of VLDL, LDL, and HDL particles each.
From the subclass levels, the weighted-mean VLDL, LDL, and
HDL particle sizes (nanometers in diameter) and particle concentrations were calculated. Lipoprotein subclasses were grouped as
large LDL (21.3–23.0 nm), intermediate LDL (19.8–21.2 nm),
small LDL (18.3–19.7 nm), large HDL (8.8–13.0 nm), medium
HDL (8.2–8.8 nm), and small HDL (7.3–8.2 nm).

Taqman allelic discrimination probes (Applied Biosystems). The
genotyped SNP rs2303790 was within Hardy-Weinberg Equilibrium in health controls (P = 0.190).
CETP concentration was determined by using a commercially
available human cholesteryl ester transfer protein ELISA Kit
(CSB-E08567h, Cusabio), which offers a detection range of
0.195–50 ng/ml. Serum samples (100 µl) were used for the assay
following dilution and preparation instructions supplied by the
vendor.
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effect estimates. The statistical packages Stata 12 and R (version
3.2.1) were used for the analyses.

Patient involvement
No patients were involved in setting the research question or
the outcome measures. Patients were not involved in developing
plans for recruitment, design, or implementation of the study or
the interpretation and presentation of results. The results of the
research will not be disseminated to the individual patient.

RESULTS

Influence of CETP D442G polymorphism on lipoprotein
phenotype
After multivariable adjustment, we found that for each
SD increase in HDL particles, a 26% increase in nAMD risk
was observed (P = 0.039). The associations between HDL
and increased risk of nAMD observed remained significant
after adjustment for the presence of the D442G polymorphism at the CETP locus (analysis performed but not
shown). To further evaluate the effect of CETP D442G
polymorphism on lipoprotein phenotypes independent of
AMD, we measured the lipoprotein profile in a further 113
non-AMD subjects who were carriers of the D442G mutation (total of 121 non-AMD subjects carrying the D442G
mutation) and compared them with 276 non-AMD controls without the mutation (Table 6). Among these nonAMD controls, presence of the CETP D442G mutation was
associated with significantly reduced level of CETP protein
(432.9 vs. 569.2 ng/ml, P < 0.001) and elevated HDL-C levels (1.5 vs. 1.3 mmol/l, P < 0.001), as expected. Comparison of lipoprotein particle concentrations showed that
D442G mutation was associated with lower medium VLDL,
higher small VLDL, and larger LDL particle size. There was
no significant difference in any of the lipoprotein particle
concentration in AMD cases according to D442G mutation
status.

TABLE 1. Baseline characteristics of controls, early AMD cases, and late AMD cases

Baseline variable

No AMD (n = 289)

Early AMD (n = 178)

nAMD (n = 193)

Pa

67.4 (9.3)
59.9
23.7 (3.8)
13.1
43.9
14.9
6.2
3.1
35.9
2.8

65.2 (9.7)
53.9
23.4 (3.7)
10.1
49.4
13.5
6.2
1.7
33.3
2.2

67.5 (10.0)
61.1
24.0 (4.0)
18.3
53.3
12.5
5.3
2.0
35.8
15.0

0.036
0.316
0.344
0.091
0.153
0.776
0.919
0.670
0.838
<0.001

1.3 (0.4)
3.1 (0.9)
1.8 (1.1)

1.3 (0.4)
3.2 (0.8)
1.8 (1.2)

1.4 (0.3)
3.0 (1.0)
1.8 (0.9)

0.214
0.136
0.819

Age (years), mean (SD)
Male, %
2
BMI (kg/m ), mean (SD)
Current smoker, %
Self-reported hypertension, %
Self-reported diabetes, %
Self-reported myocardial infarction, %
Self-reported stroke, %
On lipid medication, %
Carrier of CETP D442G variant, %
Conventional lipid biochemistry
HDL-C (mmol/l), mean (SD)
LDL-C (mmol/l), mean (SD)
TG (mmol/l), mean (SD)

a
ANOVA using an F-test was performed to compare the mean of continuous variables, whereas a chi-squared or
Fisher’s exact test was used to compare proportions for categorical variables. Fisher’s exact test was used when one
or more cells had a sample size 5.
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Lipoprotein phenotypes in nAMD cases, early AMD cases,
and controls
The baseline characteristics of participants are summarized in Table 1. Apart from slightly younger age in the
early AMD group, there were no statistically significant
differences in gender, BMI, smoking status, or history of
hypertension, diabetes, myocardial infarction, or stroke
between the three groups of patients. The proportion of
subjects on lipid medication was similar in all three groups.
The D442G minor frequency allele was present in 15.0% of
the late AMD group, 2.2% of the early AMD group, and
2.8% of controls. As expected, the presence of the D442G
polymorphism was associated with increased risk of late
AMD [OR = 6.1 (95% CI 2.7–13.7), P < 0.001]. Conventional lipid biochemistry showed similar levels of HDL-C,
LDL-C, and TGs between the three groups.
Results of detailed lipoprotein profile are summarized
in Tables 2 and 3. Although HDL-C, LDL-C, and TGs were
similar between nAMD cases and controls, more detailed
examination of the lipoprotein particle revealed significant differences between controls and patients with early
or late AMD. First, nAMD cases had lower plasma levels of
apo A-I (Apo-A1). Among the TG-rich lipoproteins, nAMD
cases had lower concentrations of VLDL and chylomicron
particles. These differences were attributable to lower concentrations of medium VLDL and chylomicron particles.
Small VLDL particle concentration did not differ between

groups. These lower levels of VLDL and chylomicron levels were associated with higher levels of IDL, but lower levels of large LDL particles. In relation to HDL particles,
nAMD cases had a higher HDL particle concentration,
which was largely due to an excess of medium HDL particles. Many of these associations showed a dose-dependent
association with early AMD cases and nAMD cases (Tables 4
and 5 and Fig. 1). In a supplementary analysis that included only subjects who were not taking any lipid-lowering medications, the associations related to ApoA1, LDL,
VLDL, and chylomicrons and IDL remained statistically
significant, whereas the associations related to HDL remained in the same direction, although not reaching statistical significance.
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TABLE 2. Comparison of lipoprotein profiles in controls, early AMD cases and nAMD cases
Pairwise comparison of meansa

Mean (SD)
No AMD (n = 289)

nAMD versus
no AMD

nAMD versus
early AMD

P for linear
b
trend

0.928
0.618
0.034
0.083

0.002
0.003
0.070
<0.001

0.017
<0.001
0.942
0.049

<0.001
0.001
0.029
<0.001

0.838
0.008
0.131

0.878
0.951
0.648

0.868
0.008
0.383

1.000
0.046
0.114

0.614
0.003
0.187

114.7 (82.6)

155.6 (110.6) <0.001

0.891

<0.001

<0.001

<0.001

554.0 (240.4)
553.7 (343.1)

448.3 (269.6) <0.001
632.6 (375.5) 0.084

0.515
0.111

<0.001
0.994

<0.001
0.129

<0.001
0.917

154.6 (23.6)
34.8 (5.2)
1,222.4 (360.8)
67.4 (28.4)

6.9 (3.6)
9.2 (4.5)
18.6 (5.7)

nAMD (n = 193)

a

P

145.3 (45.5)
0.002
37.2 (7.4)
<0.001
1,236.5 (416.9) 0.019
60.6 (23.2) <0.001

6.9 (3.5)
10.4 (5.0)
19.9 (6.4)

6.1 (5.9)
25.4 (16.2)
36.0 (17.3)

5.2 (3.8)
17.5 (12.1)
37.9 (16.5)

0.030
<0.001
0.394

0.639
0.002
0.989

0.022
<0.001
0.392

0.270
<0.001
0.555

0.008
<0.001
0.192

9.3 (0.5)
21.0 (0.6)
49.8 (8.2)

9.3 (0.5)
20.8 (0.6)
50.5 (7.6)

0.064
0.056
0.529

0.371
0.292
0.999

0.057
0.480
0.542

0.691
0.044
0.640

0.022
0.248
0.292

a
ANOVA using an F-test was performed to compare mean lipoprotein levels between the three stages of AMD, and Tukey’s honest significant
difference test was used for multiple pairwise comparisons.
b
Evidence of trend was assessed by conducting an F-test of the linear orthogonal polynomial contrast in a regression model of lipoprotein level
against AMD stage as a three-level ordinal variable.

We found a significant interaction between D442G
mutation and HDL-particle concentration on the risk of
AMD (Table 7). In noncarriers of the D442G allele, higher
levels of both total HDL and medium HDL particle
numbers were associated with increased risk of nAMD. In
carriers of the D442G allele, although there was a trend
toward higher concentration of these particles with lower
nAMD risks, the results were not statistically significant.

DISCUSSION
There is a strong biological rationale and underlying hypothesis that lipid dysregulation may be involved in the
pathogenesis of AMD. First, genetic studies have reported
variants in several C-related genes to confer increased risk
of AMD (29–32). Second, there is biochemical evidence
to suggest that intraretinal lipid transport is facilitated
by proteins similar to those in systemic lipid metabolism
(11–13). Third, patients with AMD have an increased risk
of atherosclerosis and coronary artery disease (CAD), and,
likewise, atherosclerosis and cardiovascular disease are major risk factors for development of AMD (44–48). Fourth,
studies in primates (49, 50) and rodents (15, 16) have demonstrated that oxidized lipids may accumulate in the retina
and promote angiogenesis directly or via impaired macrophage cholesterol efflux, although we acknowledge that
the relevance of these animal models to human AMD is
uncertain.
Despite the strong biological rationale, the relationship
between lipid metabolism and AMD has been inconsistently

documented in clinical studies, with most studies examining only the conventional plasma lipid measures of TC,
TG, HDL-C, and LDL-C levels. In the current study, we hypothesized that patients with AMD may have abnormal lipid
metabolism that may be reflected as changes in the subtype
of lipoprotein particles in the blood. We demonstrated that
patients with nAMD and early AMD exhibit marked differences in many lipoprotein subclasses tested compared with
controls, characterized by higher concentrations of HDL
particles, particularly medium-sized particles, and IDL particles, and lower concentrations of Apo A-1, VLDL, and chylomicron particles (Tables 2–5). These findings are in line
with the hypothesis that tissue lipids may represent therapeutic targets for the treatment and prevention of AMD.
Comparing and contrasting our observations in AMD
with the relationship between lipoprotein profile and CAD
provides insights into mechanisms. Although AMD has previously been associated with CAD, the pattern of associations of lipoprotein with AMD demonstrated in this study is
not similar to that for CAD. Specifically, high VLDL and
LDL particle concentrations are usually associated with
increased risk of CAD, whereas we found that nAMD
was associated with lower VLDL particle concentration.
Conversely, total and large HDL particle concentrations
are consistently inversely associated with CAD risk (51),
whereas in our AMD cases, the association was positive. On
the other hand, raised IDL observed in nAMD patients may
be a shared risk factor with CAD, because this is known to
be atherogenic.
We recently reported on a genome-wide association
study in East Asians and identified a strong association
Lipid metabolism and age-related macular degeneration
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Total particle concentration by subclass
ApoA1, mg/ld.
155.8 (26.7)
HDL, µmoll/l
35.3 (6.0)
LDL, nmol/l
1,320.8 (439.6)
VLDL and chylomicron
73.2 (30.5)
lipoprotein, nmol/l
Lipoprotein size distribution by subclass
HDL, µmol/l
  Large
7.1 (3.8)
  Medium
9.1 (5.0)
  Small
19.1 (6.4)
IDL, nmol/l
  IDL
110.7 (79.6)
LDL, nmol/l
  Large
581.2 (264.5)
  Small
628.8 (427.7)
VLDL and chylomicron, nmol/l
  Large
6.6 (6.3)
  Medium
30.8 (19.4)
  Small
35.8 (17.9)
Mean particle sizes
HDL particle size, nm
9.2 (0.5)
LDL particle size, nm
20.9 (0.6)
VLDL particle size, nm
49.8 (7.5)

Early AMD
versus no AMD

Early AMD (n = 178)
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TABLE 3. Comparison of lipoprotein profiles in controls, early AMD cases and nAMD cases after excluding subjects taking lipid-lowering
medications
Pairwise comparison of meansa

Mean (SD)
No AMD (n = 184)

nAMD versus
no AMD

nAMD versus
early AMD

P-value for
b
linear trend

0.953
0.422
<0.001
0.049

<0.001
0.468
0.113
<0.001

<0.001
0.081
0.387
0.284

<0.001
0.240
0.046
<0.001

0.971
0.210
0.333

0.999
0.956
0.324

0.969
0.195
0.984

0.981
0.370
0.634

0.812
0.084
0.865

120.7 (89.2)

165.3 (111.0) <0.001

1.000

<0.001

0.001

<0.001

574.0 (252.4)
543.8 (347.3)

495.2 (281.9) <0.001
656.4 (406.1) 0.034

0.121
0.034

<0.001
0.973

0.095
0.129

<0.001
0.824

153.3 (20.0)
33.9 (4.7)
1,239.5 (377.5)
66.2 (29.4)

7.0 (3.3)
9.2 (4.6)
17.7 (5.4)

nAMD (n = 95)

a

P-value

137.1 (45.8) <0.001
35.6 (7.0)
0.098
1,316.9 (449.9) <0.001
60.2 (23.9) <0.001

6.9 (3.5)
10.1 (5.7)
18.6 (5.7)

6.1 (6.0)
24.9 (16.4)
35.2 (18.7)

5.2 (3.8)
17.3 (11.4)
37.7 (17.8)

0.078
<0.001
0.610

0.514
0.008
0.846

0.065
<0.001
0.836

0.499
0.004
0.581

0.025
<0.001
0.569

9.3 (0.5)
21.0 (0.6)
49.8 (8.3)

9.4 (0.5)
20.9 (0.6)
50.3 (7.8)

0.031
0.169
0.647

0.134
0.216
0.907

0.045
0.977
0.622

0.840
0.241
0.877

0.017
0.837
0.354

a

ANOVA using an F-test was performed to compare mean lipoprotein levels between the three stages of AMD, and Tukey’s honest significant
difference test was used for multiple pairwise comparisons.
b
Evidence of trend was assessed by conducting an F-test of the linear orthogonal polynomial contrast in a regression model of lipoprotein level
against AMD stage as a three-level ordinal variable.

between the CETP D442G mutation with nAMD (per-allele
OR = 1.70) (33). CETP mediates the transfer of cholesteryl
ester from HDL to LDL. Together with hepatic lipase LIPC,
these two genes are the key genetic determinants of lipoprotein sizes (52, 53). The D442G mutation is specific to
Asians, with minor allele frequency of 0.03 in East Asians
and <0.01 in Europeans. The mutant 442G allele is known
to impair CETP function, resulting in reduced CETP mass
and activity (34, 35, 54). Each copy of the dysfunctional
442G allele conferred, on average, a rise in HDL-C levels of
0.174 mmol/l. We were therefore particularly interested to
investigate the potential influence of HDL particles on
AMD risk. Our results demonstrated that increase in HDL
particle concentration, particularly medium-sized particles,
was significantly associated with nAMD.
To understand this association, we need to understand
the function of HDL described in previous studies. HDL
play a unique role in supporting reverse C transport, which
represents a major pathway through which excess C in peripheral tissues, such as endothelium, can be removed.
These particles therefore protect against effects from excess C in the peripheral tissues (55–57). Accumulation of
intracellular C may also result from aging of macrophages,
with features including abnormal polarization, downregulation of ABCA1, and impaired C efflux, which, in turn,
can lead to increased inflammation and a proangiogenic
state (15). HDL-C may also have additional antiinflammatory, antioxidant, antiaggregatory, anticoagulant, and profibrinolytic activities. However, these protective properties
of HDL may vary according to the structure and function
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of the lipoprotein particles on which they are carried.
Thus, our finding that risk of AMD was not associated with
HDL-C, but was associated with the number of particles
(particularly of medium-sized HDL particles), is interesting, but not altogether surprising. In addition, our finding
of reduced concentration of Apo A-1 in patients with
nAMD further supports that the structure and function of
HDL particles may be altered in AMD. Apo-A1 is a major
apolipoprotein in HDL and one that is thought to mediate
many of the protective effects of HDL. This suggests that
the number of HDL particles, while increased, may be depleted of Apo-A1, adversely affecting their ability to facilitate cholesterol efflux. In support of this hypothesis, within
the retina, Apo-A1 has been observed in the apical region
of the RPE, in the interphotoreceptor matrix of rod photoreceptors, choroid, and neuroretina in monkey retina. The
apical location within the RPE suggests that Apo-A1 may be
secreted by RPE into the interphotoreceptor matrix (21).
One proposed mechanism in which RPE can remove oxidized lipids arising in the photoreceptor outer segments
may be through transfer of the lipids into their endogenous Apo-A1- and ApoE-containing HDL-like particles,
which are, in turn, transported by ABCA1 out of the RPE.
However, these endogenous HDL-like particles remain to
be identified.
Although we confirmed our a priori hypothesis that perturbation in HDL metabolism would be the main changes
seen in AMD, we were somewhat surprised to find that
VLDL and chylomicron lipoprotein concentration was
markedly reduced in subjects with AMD. In the retina,
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Total particle concentration by subclass
ApoA1, mg/dl
154.4 (27.0)
HDL, µmol/l
34.8 (6.0)
LDL, nmol/l
1,426.5 (457.7)
VLDL and chylomicron
74.2 (31.0)
lipoprotein, nmol/l
Lipoprotein size distribution by subclass
HDL, µmol/l
  Large
7.0 (3.9)
  Medium
9.0 (5.2)
  Small
18.8 (6.6)
IDL, nmol/l
  IDL
120.6 (81.2)
LDL, nmol/l
  Large
637.7 (286.7)
  Small
668.2 (473.4)
VLDL and chylomicron, nmol/l
  Large
6.8 (6.7)
  Medium
31.0 (20.0)
  Small
36.4 (18.3)
Mean particle sizes
HDL particle size, nm
9.2 (0.5)
LDL particle size, nm
20.9 (0.6)
VLDL particle size, nm
49.4 (7.8)

Early AMD
versus no AMD

Early AMD (n = 121)
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TABLE 4. Relationship between the nAMD and early AMD with lipoprotein profiles
Early AMD versus controls
a

Pb

0.664
0.536
0.639

1.33 (1.03–1.71)
0.87 (0.69–1.11)
1.03 (0.78–1.35)

0.027
0.265
0.849

0.86 (0.68–1.04)
0.79 (0.63–1.00)
0.71 (0.55–0.90)
0.84 (0.68–1.04)

0.105
0.053
0.005
0.105

0.68 (0.57–0.82)
1.26 (1.01–1.57)
0.80 (0.63–1.02)
0.54 (0.41–0.71)

<0.001
0.039
0.076
<0.001

0.88 (0.70–1.11)
0.98 (0.80–1.21)
0.90 (0.72–1.11)

0.287
0.877
0.321

0.92 (0.71–1.18)
1.24 (1.01–1.52)
1.07 (0.86–1.34)

0.495
0.039
0.523

1.06 (0.86–1.29)

0.595

1.68 (1.38–2.04)

<0.001

0.84 (0.68–1.04)
0.78 (0.62–0.99)

0.116
0.041

0.57 (0.44–0.72)
0.98 (0.78–1.23)

<0.001
0.865

0.90 (0.72–1.12)
0.74 (0.59–0.93)
1.03 (0.84–1.27)

0.351
0.009
0.754

0.63 (0.47–0.86)
0.30 (0.21–0.43)
1.10 (0.89–1.37)

0.003
<0.001
0.356

1.11 (0.89–1.38)
1.11 (0.90–1.37)
0.99 (0.81–1.21)

0.355
0.341
0.904

1.36 (1.08–1.71)
0.93 (0.74–1.17)
1.04 (0.84–1.30)

0.010
0.559
0.713

P

1.05 (0.84–1.31)
1.07 (0.86–1.35)
0.95 (0.77–1.18)

a
The OR relating a one SD increase in lipoprotein to early/late stage AMD was estimated from separate multiple
logistic regression models adjusted for age, gender, BMI, smoking status, average axial length, lipid-lowering
medication, self-reported hypertension, diabetes, myocardial infarction, and stroke.
b
P-values were derived from Wald tests of the corresponding logistic regression coefficient relating each
lipoprotein to early/late-stage AMD.

studies have demonstrated that LDL is the major carrier
of cholesterol from the systemic circulation into RPE and
neurosensory retina (58–60). Although the function of
these lipids within the retina remain to be elucidated,
recent findings using VLDL receptor (VLDLR) KO mice
suggest that lipid -oxidation is an important energy
source for the retina. Fuel shortage resulting from reduced
uptake of TG-derived fatty acid and glucose, in turn, leads to
pathological angiogenesis in the retina through stabilization of hypoxia-induced factor 1a and secretion of vascular
endothelial growth factor A by photoreceptors (58–60).
The relevance of the VLDLR to the pathogenesis of AMD
is further supported by genetic association studies (61).
The finding of markedly reduced VLDL particle concentration from the current study further supports the hypothesis that eyes with AMD require fatty acids from VLDL.
It is our hypothesis that the reduced availability of VLDL
results in reduced fatty acid uptake by the retinal cells, which
may, in turn, result in a proangiogenic state. The mechanism leading to the low VLDL in AMD patients is unclear,
but may include reduced production from the liver, increased catabolism by LPL, and increased uptake by tissues
other than the eye. However, associations between variants
at the LPL locus and increased susceptibility to AMD have
so far been inconsistently described (29, 62, 63).
We explored the possibility that the presence of the
D442G mutation at the CETP locus may explain the association between lipoprotein particle concentrations and

AMD (Table 6). In controls, the presence of the 442G allele was associated with lower CETP activity and higher
HDL-C, a finding that is consistent with previous studies
(54, 64, 65). However, inclusion of the D442G mutation in
the model did not significantly alter the association between
HDL particle concentrations and increased risk of nAMD.
As such, factors other than this mutation in CETP must play
an important role in the pathogenesis of dyslipidemia associated with AMD. First, other mutations at the CETP locus may be important. Six polymorphisms in CETP have
previously been described (26). Of specific relevance, the
presence of the V405 allele of rs5882 has a similar, but
smaller, effect to D442G mutation and is associated with
higher HDL-C and reduced CETP activity. This polymorphism has been reported to be associated with polypoidal
choroidal vasculopathy, a subtype of AMD common in
Asians (62). Second, the effect of CETP mutations on AMD
risk may not be mediated through HDL particles in the
systemic circulation, but by a local effect in the retina.
Indeed, CETP has been localized to the outer plexiform
layer and the photoreceptor outer segments and interphotoreceptor matrix in monkey retina (21), suggesting that
the retina has the ability to mature HDL particles locally
and to transfer cholesterylester between lipoproteins.
Therefore, dysfunction in CETP could lead to localized
impairment of HDL maturation within the retina, resulting in impaired lipid transfer between the RPE and
photoreceptors.
Lipid metabolism and age-related macular degeneration
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Conventional lipid biochemistry
HDL-C, mmol/l
LDL-C, mmol/l
TG, mmol/l
Total particle concentration by subclass
ApoA1, mg/dl
HDL particles (total,) µmol/l
LDL particles (total), nmol/l
VLDL and chylomicron particles (total), nmol/l
Lipoprotein size distribution by subclass
HDL
  Large
  Medium
  Small
IDL
  IDL particles
LDL
  Large
  Small
VLDL and chylomicron
  Large
  Medium
  Small
Mean particle sizes
HDL particle size
LDL particle size
VLDL particle size

nAMD versus controls
ORa (95% CI)

OR (95% CI)

b
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TABLE 5. Relationship between the nAMD and early AMD with lipoprotein profiles after excluding subjects taking lipid-lowering medications
Early AMD versus controls
a

OR (95% CI)

P

a

OR (95% CI)

Pb

1.12 (0.84–1.50)
0.89 (0.67–1.16)
0.96 (0.75–1.24)

0.431
0.395
0.768

1.54 (1.11–2.14)
0.85 (0.65–1.12)
0.97 (0.68–1.38)

0.010
0.252
0.847

0.918 (0.67–1.23)
0.81 (0.61–1.09)
0.67 (0.42–0.78)
0.73 (0.56–0.96)

0.536
0.166
<0.001
0.027

0.64 (0.51–0.81)
1.19 (0.90–1.59)
0.73 (0.55–0.99)
0.51 (0.36–0.72)

<0.001
0.227
0.040
<0.001

0.97 (0.72–1.31)
1.03 (0.80–1.32)
0.83 (0.63–1.10)

0.848
0.845
0.193

1.10 (0.80–1.52)
1.25 (0.98–1.60)
0.89 (0.66–1.194)

0.554
0.073
0.435

1.03 (0.81–1.31)

0.807

1.64 (1.28–2.10)

<0.001

0.77 (0.60–0.98)
0.69 (0.52–0.93)

0.036
0.013

0.61 (0.46–0.81)
0.89 (0.67–1.18)

<0.001
0.422

0.89 (0.68–1.16)
0.71 (0.54–0.95)
0.88 (0.68–1.14)

0.378
0.020
0.335

0.64 (0.44–0.93)
0.30 (0.19–0.47)
1.01 (0.78–1.32)

0.020
<0.001
0.913

1.29 (0.98–1.70)
1.22 (0.94–1.60)
1.06 (0.83–1.35)

0.070
0.140
0.652

1.75 (1.28–2.40)
1.10 (0.82–1.49)
1.10 (0.84–1.45)

<0.001
0.520
0.477

a
The OR relating a one SD increase in lipoprotein to early/late stage AMD was estimated from separate multiple logistic regression models
adjusted for age, gender, BMI, smoking status, average axial length, lipid-lowering medication, self-reported hypertension, diabetes, myocardial
infarction, and stroke.
b
P-values were derived from Wald tests of the corresponding logistic regression coefficient relating each lipoprotein to early/late-stage AMD.

There are limitations in the current study. Changes demonstrated in plasma may not reflect the exact changes
within the chorioretina. Future studies should aim to incorporate evaluation of cholesterol metabolism within the
retina. In particular, further experiments based on human
tissues will be needed to ascertain the translatability of
studies in rodents and primates. Although we demonstrated marked changes in all the subclasses of lipoproteins
tested, we were not able to evaluate the relative influence
of different pathways. Knowledge of which pathways are the
most important will be essential in guiding future therapeutic approaches. Because of the limited number of patients
with nAMD in population studies, our case-control study
compared subjects from a hospital-based cohort (the Asian
AMD Phenotyping study) with those from a populationbased study (the Singapore Chinese Eye Study). Thus, despite the carefully designed and standardized protocols
between the two studies, we acknowledge that there remain
inherent differences in cases and controls, and the possibility of selection bias. Approximately 35% of subjects in each
AMD category was on lipid-lowering medication. However,
it is unlikely that the associations reported are affected by
lipid medication because we have included lipid-lowering
medication as one of the variables in the multivariable
models, and most of the associations remained significant,
even in a subgroup analysis that included only subjects not
taking lipid-lowering medications. Finally, blood samples
were in nonfasting conditions. Ideally, we would have collected the samples in the fasting state. However, the controls
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in this study were collected as part of a much larger study
to examine the prevalence and risk factors of a number of
different eye diseases in the Singapore population. Multiple complex measurements related to eye disease were required, and, logistically, we were not able to study all the
participants in the fasting state. For this reason, we collected the blood samples from cases in the nonfasting state
as well. We believe that lipid measurements in nonfasting
samples would still be relevant. Most humans spend their
day in the nonfasting state, and, therefore, the nonfasting
state may actually be more physiologically relevant to
health and disease than the fasting state. The use of fasting
lipids for predicting the risk of future disease is largely historical, and, for most purposes, measurement of lipids in
the fasting state is considered preferable but not essential
(66). In fact, the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory
Medicine recently issued a statement suggesting that fasting is not essential for determination of a lipid profile in
relation to predicting cardiovascular disease and making
decisions on treatment. This is based on studies that have
shown that nonfasting lipids are as (if not more) predictive
of cardiovascular disease as fasting lipids (67, 68). This
does not exclude the possibility that differences in the timing of blood sampling in relation to the last meal prior to
blood sampling could bias the results. We feel that the pattern of lipoproteins associated with AMD in this instance
makes it less likely that our findings merely reflect bias
due to the nonfasting samples. First, TG is one of the blood
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Conventional lipid biochemistry
HDL-C, mmol/l
LDL-C, mmol/l
TG, mmol/l
Total particle concentration by subclass
ApoA1, mg/dl
HDL particles (total,) µmol/l
LDL particles (total), nmol/l
VLDL and chylomicron particles (total), nmol/l
Lipoprotein size distribution by subclass
HDL
  Large
  Medium
  Small
IDL
  IDL particles
LDL
  Large
  Small
VLDL and chylomicron
  Large
  Medium
  Small
Mean particle sizes
HDL particle size
LDL particle size
VLDL particle size

nAMD versus controls
b
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TABLE 6. Lipoprotein profiles in controls and late AMD cases according to CETP D442G status
Pa

Mean (SD)
Controls
Without D442G
(n = 276)

CETP concentration, ng/ml

LDL
  Large
  Small
VLDL and chylomicron
  Large
  Medium
  Small
Mean particle size
   HDL particles, nm
   LDL particles, nm
   VLDL and chylomicron, nm

Without D442G
(n = 164)

With D442G
(n = 29)

Controls

Late AMD

Without versus
with D442G

Without versus
with D442G

569.2 (232.2)

432.9 (189.5)

538.1 (302.7)

528.9 (342.7)

<0.001

0.773

1.3 (0.4)
3.1 (0.9)
1.8 (1.1)

1.5 (0.5)
3.4 (0.9)
1.8 (1.2)

1.4 (0.3)
3.0 (1.0)
1.9 (1.0)

1.5 (0.4)
2.9 (1.0)
1.6 (0.7)

<0.001
0.247
0.515

0.497
0.892
0.509

0.529
0.379
0.387
0.674

0.968
0.272
0.487
0.303

155.1 (26.4)
35.1 (6.0)
1,326.5 (446.0)
73.3 (30.4)

160.3 (25.0)
144.2 (47.0)
151.4 (35.8)
36.9 (6.2)
37.1 (7.4)
37.9 (7.2)
1,316.4 (428.2) 1,264.9 (425.3) 1,076.4 (328.6)
71.6 (26.8)
61.3 (24.0)
56.4 (17.2)

7.0 (3.7)
9.0 (5.0)
19.2 (6.3)

7.9 (3.9)
9.3 (4.7)
19.8 (5.7)

6.7 (3.2)
10.4 (5.1)
20.1 (6.6)

8.2 (4.8)
10.7 (4.4)
19.0 (4.8)

0.092
0.728
0.710

0.308
0.255
0.512

110.9 (80.2)

124.4 (92.2)

157.5 (112.0)

145.2 (103.5)

0.111

0.726

578.2 (268.4)
637.5 (430.5)

633.2 (269.7)
558.8 (431.3)

443.1 (260.5)
664.2 (386.2)

477.6 (320.0)
453.6 (243.8)

0.294
0.069

0.319
0.122

6.7 (6.4)
31.0 (19.5)
35.6 (17.9)

6.7 (5.5)
23.5 (16.0)
41.4 (18.7)

5.2 (3.9)
18.1 (12.6)
38.0 (16.6)

5.1 (3.3)
14.4 (7.7)
36.9 (15.9)

0.973
0.003
<0.001

0.292
0.191
0.773

9.2 (0.5)
20.9 (0.6)
49.8 (7.6)

9.3 (0.5)
21.1 (0.7)
50.9 (7.8)

9.3 (0.5)
20.8 (0.6)
50.4 (7.5)

9.4 (0.5)
21.0 (0.6)
51.6 (8.1)

0.088
0.003
0.192

0.115
0.346
0.450

a
P-values were derived from t-tests of the adjusted difference in mean lipoprotein level between mutation carriers and noncarriers (for cases and
controls separately) in a multiple linear regression model adjusted for age, gender, BMI, smoking status, average axial length, lipid-lowering
medication, self-reported hypertension, diabetes, myocardial infarction, and stroke.

lipids that is most affected by food intake and is, on average, 0.3 mmol/l higher in nonfasting samples than in fasting samples (67). We did not see any significant differences
in TG levels between cases and controls. Second, postprandial changes in lipoprotein particles have been studied
using NMR in more than 1,000 men and women (69). In
this study, both men and women exhibited a reduction
in the total LDL-particle concentration following a meal,
which was associated with an increase in IDL and large
LDL particles and a reduction in small LDL particles. In

our study, we observed reduced total LDL particle concentration, increased IDL particle concentration, and reduced
small LDL particle concentration. However, unlike the
observation following a meal, when large LDL particle
concentration increased, we observed a reduction in
large LDL particle concentrations, which was highly statistically significant. This suggests that the differences observed between cases and controls may not relate to food
intake. To further evaluate the potential effects of differences in the way samples were collected among cases and

TABLE 7. Interaction between HDL particle concentration and CETP D442G mutation on the risk of nAMD
Group without D442G
mutation (n = 440)

Group with D442G
mutation (n = 37)

b

Interaction coefficient

Number with AMD
164
29
—
Percentage with AMD (%)
37.3
78.4
—
Effect of total HDL particle concentration on AMD
a
OR per SD increase in total 1.32 (1.06–1.65) P = 0.014 0.44 (0.16–1.20) P = 0.107 0.33 (0.12–0.93) P = 0.036
HDL particle concentration
Effect of medium-sized HDL particle concentration on AMD:
a
1.30 (1.06–1.61) 0.014
0.34 (0.10–1.18) 0.088
0.26 (0.07–0.92) 0.037
OR per SD increase in
medium-sized HDL particle
concentration
a
The OR relating increase in each lipoprotein to late-stage AMD by mutation carrier status was estimated from
a logistic regression model that included an interaction term between the lipoprotein and mutation status, in
addition to their primary effects, age, gender, BMI, smoking status, average axial length, lipid-lowering medication,
self-reported hypertension, diabetes, myocardial infarction, and stroke.
b
The interaction coefficient estimates the ratio of the OR in mutation carriers to that in noncarriers in the
abovementioned model, with the P-value derived from a Wald test of the said coefficient.
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Conventional lipid biochemistry
HDL-C, mmol/l
LDL-C, mmol/l
TG, mmol/l
Total particle concentration by subclass
ApoA1, mg/dl
HDL, µmol/l
LDL, nmol/l
VLDL and chylomicron lipoprotein, nmol/l
Lipoprotein size distribution by subclass
HDL
  Large
  Medium
  Small
IDL

Late AMD

With D442G
(n = 121)

Pa
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CONCLUSION
To conclude, we demonstrate that altered concentration of lipoprotein particles are associated with AMD that
are not captured by conventional lipid measures. We report that nAMD is associated with higher concentrations
of HDL particles, particularly medium-sized HDL particles, and IDL particles, and lower concentration of VLDL
and chylomicron and Apo A-1. These relationships were
not mediated by the CETP D442G mutation. However, the
associations may be modulated by the presence of this mutation. Although our study does not provide definitive
proof of a causal link between dyslipidemia and AMD, it
does support the relevance of the VLDLR KO mouse
model of AMD to humans and raises the possibility that
therapies that increase the supply of fatty acids through
VLDL to the retina, or that may reduce the reliance on
lipids as a fuel, could be relevant to the prevention and
treatment of AMD.
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controls, we also evaluated the lipoprotein particle concentrations in 17 subjects from the Singapore Chinese Eye
Study who had nAMD and had blood available that had
been collected at the same time and using the same protocol as the controls utilized in this study. The results from
these 17 subjects are presented alongside our findings in
supplemental Table S1. The low concentrations of medium
VLDL and large LDL particles, accompanied by high concentrations of IDL particles that we observed in cases compared with controls were also observed in these 17 cases
derived from the Singapore Chinese Health Study (the
study from which the controls were derived). In relation to
HDL, there was a relatively larger proportion of large HDL
particles in these cases compared with controls (as we saw
with the other cases), reflected as a larger HDL particle
size. However, the concentrations of the individual HDL
species were dissimilar from the other cases. Chylomicron
concentrations were also different in these 17 cases compared with the cases derived from the Asian AMD phenotyping study. Thus, although we are reasonably confident
in our findings related to VLDL, IDL, and LDL particles,
we feel that some of these studies should be repeated in
a study with fasting collection of samples, which may be
particularly relevant to our understanding of the role of
chylomicron and HDL particles in the pathogenesis of
AMD.
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